DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Results Conference Call March 20, 2024 8:00 AM ET Company Participants Dietrich Pauls - President, CEO & Director Lorianne Masuoka - Chief Medical Officer Scott Kellen - CFO & Company Secretary Conference Call Participants Thomas Flaten - Lake Street Capital François Brisebois - Oppenheimer Alex Nowak - Craig-Hallum Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Full Year 2023 Conference Call. An audio recording of the ...

DiaMedica Therapeutics (NASDAQ:DMAC) just reported results for the fourth quarter of 2023.DiaMedica Therapeutics reported earnings per share of -14 cents. This met the analyst estimate for EPS of -14 cents.The company did not report any revenue for the quarter.InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to __________________. Commission file number: 001-36291 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia (State or other jurisdiction of incorporation or organization) 301 Carlson Parkway, Suite 210 Minneapolis, Minnesota (Address of princ ...

Exhibit 99.1 DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results Conference Call and Webcast March 20 at 8:00 AM Eastern Time / 7:00 AM Central Time Minneapolis, Minnesota – March 19, 2024 (Business Wire) – DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the year ended Decembe ...

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the year ended December 31, 2023. Management will host a conference call Wednesday, March 20, 2024, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and full year 2023 financial results. ReMEDy2 Phase 2/3 AIS Cli ...

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke (AIS), today announced a poster presentation of the design and rationale for ReMEDy2, the planned pivotal phase 2/3 trial of DM199 in AIS patients, at the American Heart Association 2024 International Stroke Conference being held in Phoenix, AZ from February 7 – 9, 2024. For information about t ...

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2023 Earnings Call Transcript November 14, 2023 8:00 AM ET Company Participants Rick Pauls - President and CEO Scott Kellen - CFO Conference Call Participants Thomas Flaten - Lake Street Capital Alexander Nowak - Craig-Hallum Capital Group Francois Brisebois - Oppenheimer. Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Third Quarter 2023 Conference Call. An audio recording of the webcast will be available shortly after the ...

1 Cautionary Note Regarding Forward-Looking Statements Other risk and uncertainties of which DiaMedica is not currently aware may also affect the Company's forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. All forward-looking statements contained in this presentation speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. DiaMedica undertakes no obligation to publicl ...

[PART I. FINANCIAL INFORMATION](index=6&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) This section presents the company's unaudited condensed consolidated financial statements, management's discussion and analysis, market risk disclosures, and controls and procedures for the reporting period [Financial Statements](index=6&type=section&id=Item%201.%20Financial%20Statements) The unaudited condensed consolidated financial statements for the period ended September 30, 2023, show a significant increase in total assets and shareholders' equity, primarily due to proceeds from a private placement, while the net loss widened due to increased research and development expenses, with no revenue from product sales Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | Sep 30, 2023 | Dec 31, 2022 | | :--- | :--- | :--- | | Cash and cash equivalents | $2,232 | $4,728 | | Total current assets | $47,886 | $33,835 | | Total assets | $58,139 | $34,395 | | Total current liabilities | $2,170 | $2,168 | | Total shareholders' equity | $55,629 | $31,827 | Condensed Consolidated Statements of Operations Highlights (in thousands) | Metric | Three Months Ended Sep 30, 2023 | Three Months Ended Sep 30, 2022 | Nine Months Ended Sep 30, 2023 | Nine Months Ended Sep 30, 2022 | | :--- | :--- | :--- | :--- | :--- | | Research and development | $3,272 | $1,640 | $9,433 | $5,569 | | General and administrative | $1,885 | $1,488 | $5,986 | $4,459 | | Operating loss | ($5,157) | ($3,128) | ($15,419) | ($10,028) | | Net loss | ($4,471) | ($3,059) | ($14,220) | ($9,925) | | Basic and diluted net loss per share | ($0.12) | ($0.12) | ($0.46) | ($0.38) | Condensed Consolidated Statements of Cash Flows Highlights (in thousands) | Cash Flow Activity | Nine Months Ended Sep 30, 2023 | Nine Months Ended Sep 30, 2022 | | :--- | :--- | :--- | | Net cash used in operating activities | ($14,916) | ($8,745) | | Net cash (used in) provided by investing activities | ($24,423) | $6,814 | | Net cash provided by (used in) financing activities | $36,843 | ($5) | | Net decrease in cash and cash equivalents | ($2,496) | ($1,936) | [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=19&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's focus on developing its lead candidate, DM199, for acute ischemic stroke (AIS) and cardio-renal disease (CRD), highlighting the recent lifting of the FDA clinical hold on the ReMEDy2 trial, the financial impact of increased R&D and G&A expenses, and the significant boost to liquidity from private placements in April and June 2023, providing sufficient capital for at least the next 12 months - The company's primary focus is advancing its lead candidate **DM199**, a recombinant form of human tissue kallikrein-1 (KLK1), for the treatment of acute ischemic stroke (AIS) and cardio-renal disease (CRD)[67](index=67&type=chunk) - In June 2023, the FDA lifted the clinical hold on the Phase 2/3 ReMEDy2 trial for DM199 in AIS, allowing the company to resume preparations for the trial[70](index=70&type=chunk) Comparison of Operating Expenses (in thousands) | Expense Category | Three Months Ended Sep 30, 2023 | Three Months Ended Sep 30, 2022 | Nine Months Ended Sep 30, 2023 | Nine Months Ended Sep 30, 2022 | | :--- | :--- | :--- | :--- | :--- | | Research and development | $3,272 | $1,640 | $9,433 | $5,569 | | General and administrative | $1,885 | $1,488 | $5,986 | $4,459 | - The company raised **$36.8 million** in net proceeds from private placements in April and June 2023, which is expected to fund planned operations for at least the next 12 months[74](index=74&type=chunk)[94](index=94&type=chunk) Liquidity and Capital Resources Summary (in thousands) | Metric | Sep 30, 2023 | Dec 31, 2022 | | :--- | :--- | :--- | | Cash, cash equivalents and marketable securities | $56,212 | $33,502 | | Working capital | $45,716 | $31,667 | [Quantitative and Qualitative Disclosures about Market Risk](index=26&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) As a smaller reporting company, DiaMedica Therapeutics Inc. is not required to provide disclosure for this item - The company is not required to provide disclosure pursuant to this item as it qualifies as a smaller reporting company[99](index=99&type=chunk) [Controls and Procedures](index=26&type=section&id=Item%204.%20Controls%20and%20Procedures) Management, including the CEO and CFO, evaluated the company's disclosure controls and procedures and concluded they were effective as of September 30, 2023, with no material changes to the company's internal control over financial reporting during the quarter - Based on an evaluation as of the end of the reporting period, the Chief Executive Officer and Chief Financial Officer concluded that the company's disclosure controls and procedures were **effective**[100](index=100&type=chunk) - No changes in internal control over financial reporting occurred during the third quarter of 2023 that have materially affected, or are reasonably likely to materially affect, these controls[101](index=101&type=chunk) [PART II. OTHER INFORMATION](index=27&type=section&id=PART%20II.%20OTHER%20INFORMATION) This section details legal proceedings, new risk factors related to financial institution stability, unregistered equity sales, and a list of exhibits filed with the report [Legal Proceedings](index=27&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in litigation with Pharmaceutical Research Associates Group B.V. (ICON/PRA Netherlands), where a Dutch court ruled in DiaMedica's favor affirming its ownership of clinical study documents, a decision that ICON/PRA Netherlands has appealed with a primary case hearing scheduled for December 2023 - The company is in a legal dispute with ICON/PRA Netherlands regarding the possession of clinical study documents[103](index=103&type=chunk) - On April 21, 2023, the Netherlands Commercial Court (NCC) issued a judgment affirming DiaMedica's ownership of the documents; ICON/PRA Netherlands filed an appeal on June 15, 2023, and a hearing for the primary case is scheduled for **December 7, 2023**[104](index=104&type=chunk) [Risk Factors](index=27&type=section&id=Item%201A.%20Risk%20Factors) A new risk factor has been added regarding the potential impact of financial institution instability, acknowledging that disruptions in the banking sector could adversely affect the company's ability to access cash deposits, obtain financing, and meet liquidity requirements following bank failures in early 2023 - A new risk factor was disclosed concerning the stability of financial institutions, prompted by the bank failures of Silicon Valley Bank, Signature Bank, and First Republic Bank in early 2023[106](index=106&type=chunk) - The risk highlights that future disruptions could adversely affect the company's ability to access its cash, obtain financing, or meet liquidity requirements, and could also impact its suppliers and vendors[106](index=106&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=28&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported that it did not sell any unregistered equity securities during the third quarter ended September 30, 2023 - No unregistered equity securities were sold during the quarter ended September 30, 2023[107](index=107&type=chunk) [Exhibits](index=28&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed with the quarterly report, including corporate governance documents, material contracts, and certifications by the CEO and CFO as required by the Sarbanes-Oxley Act - The report includes a list of exhibits filed, such as the Notice of Articles, Amended and Restated Articles, a Consulting Services Agreement, a Separation Agreement, and various officer certifications[111](index=111&type=chunk)[112](index=112&type=chunk)

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q2 2023 Earnings Call Transcript August 15, 2023 8:00 AM ET Company Participants Rick Pauls - President and CEO Scott Kellen - CFO Conference Call Participants Thomas Flaten - Lake Street Capital Alex Nowak - Craig-Hallum Capital Group Dan Hultberg - Oppenheimer Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Second Quarter 2023 Conference Call. An audio recording of the webcast will be available shortly after the call today on ...